Breaking News Instant updates and real-time market news.

OPHT

Ophthotech

$34.54

-4.42 (-11.35%)

, REGN

Regeneron

$390.38

-7.78 (-1.95%)

07:13
11/29/16
11/29
07:13
11/29/16
07:13

Ophthotech has no read through from competitor failure, says SunTrust

After Regeneron's (REGN) REGN2176-3 for wet AMD failed to show significant efficacy in a Phase II trial, SunTrust analyst Yatin Suneja does not believe that the failure bodes badly for Ophthotech (OPHT) whose Fovista treatment, like Regeneron's (REGN) drug, utilizes the PDGF pathway. The analyst says that Ophthotech's Fovista "has shown impressive efficacy in both Phase I and Phase IIb studies," and Suneja expects Fovista's Phase III results to also show strong efficacy. The analyst reiterates a $100 price target and a Buy rating on Ophthotech.

OPHT

Ophthotech

$34.54

-4.42 (-11.35%)

REGN

Regeneron

$390.38

-7.78 (-1.95%)

  • 03

    Dec

  • 29

    Mar

OPHT Ophthotech
$34.54

-4.42 (-11.35%)

09/09/16
LEER
09/09/16
NO CHANGE
LEER
Leerink updates therapeutics best ideas for 2016
In a note to investors this morning, Leerink has updated its best ideas for 2016 from the firm's five therapeutics analysts. The list includes Alexion (ALXN), Dermira (DERM), Intra-Cellular (ITCI), Sanofi (SNY), Allergan (AGN), Alnylam (ALNY), Innate Pharma (IPHYF), The Medicines Co. (MDCO), and Ophthotech (OPHT).
09/30/16
COWN
09/30/16
NO CHANGE
Target $60
COWN
Outperform
Ophthotech price target lowered to $60 from $80 at Cowen
Cowen analyst Tyler Van Buren said that Regeneron's (REGN) Phase 2 data for aflibercept co-formulated with rinucumab is negative for the class of anti-PDGFs as a whole and lowered his price target on Ophthotech (OPHT) to $60 from $80 after lowering his view of the probability of the success of its own wet AMD treatment to 50%. However, if a 3-4 letter benefit if observed when the Phase III trials read out in December, upside of $80-$120 per share from current levels is still possible, said Van Buren, who keeps an Outperform rating on Ophthotech shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.
10/06/16
GSCO
10/06/16
NO CHANGE
Target $23
GSCO
Sell
Ophthotech price target lowered to $23 from $45 at Goldman
Goldman analyst Terence Flynn lowered Ophthotech's (OPHT) price target to $23 from $45 and reiterated his Sell rating. He revised is thesis on Ophthotech following Regeneron's (REGN) recent negative Phase II data for its co-formulation of Eylea with Rinucumab and is incrementally more cautious on success for Fovista currently in Phase III trials.
REGN Regeneron
$390.38

-7.78 (-1.95%)

11/07/16
CHDN
11/07/16
NO CHANGE
CHDN
Regeneron shyness on drug prices negative, says Chardan
Chardan analyst Gbola Amusa says that Regeneron's reluctance to comment on drug pricing pressures during its Q3 earnings call is very unusual for a large drug company. The analyst says that this development creates risk that "pricing dynamics for Regeneron are either unknown...or are perhaps so negative that consensus estimates would be downwardly revised if a robust discussion were to have occurred." The analyst believes that, for Regeneron's Eylea treatment to meet consensus estimates, data on three upcoming, competing products will have to be negative, and all pricing pressure on drugs would have to disappear. He keeps a Sell rating on the stock.
11/07/16
LEER
11/07/16
NO CHANGE
Target $504
LEER
Outperform
Regeneron price target lowered to $504 from $513 at Leerink
Leerink analyst Geoffrey Porges lowered his price target for Regeneron (REGN) to $504 from $513 on valuation. Porges expects near-term volatility for the stock given questions regarding the upcoming second interim analysis of the Odyssey Outcomes trial for Praluent, the restart of trials for pain treatment fasinumab after the FDA's clinical hold, and the issues regarding development partner Sanofi's (SNY) fill-finish plant leading to sarilumab's Complete Response Letter last week. He reiterates an Outperform on Regeneron's shares.
11/14/16
PIPR
11/14/16
NO CHANGE
PIPR
Piper sees Biotech rally continuing into 2017, lays out five to own
Piper Jaffray analyst Edward Tenthoff expects the rally in Biotechs, following "the trifecta" of a Trump Presidential election, Republican Congress sweep and defeat of Prop 61 in California, to continue into 2017. He recommends focusing on shares of Vertex (VRTX), Regeneron (REGN), Alnylam (ALNY), Exelixis (EXEL) and OncoMed (OMED). Tenthoff has a Neutral rating on Regeneron and Overweight ratings on the other four names.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.

TODAY'S FREE FLY STORIES

WFC

Wells Fargo

$53.00

-0.5 (-0.93%)

19:34
04/23/17
04/23
19:34
04/23/17
19:34
Periodicals
Two California retirement systems vote against Wells directors, Reuters says »

Two of California's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 11

    May

  • 13

    Jul

  • 12

    Oct

  • 15

    Jan

AAL

American Airlines

$45.15

-0.07 (-0.15%)

, UAL

United Continental

$69.56

-0.24 (-0.34%)

19:22
04/23/17
04/23
19:22
04/23/17
19:22
Periodicals
American Airlines suspends flight attendant after Friday altercation, WSJ says »

Video of an American…

AAL

American Airlines

$45.15

-0.07 (-0.15%)

UAL

United Continental

$69.56

-0.24 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

FB

Facebook

$143.68

-0.12 (-0.08%)

19:11
04/23/17
04/23
19:11
04/23/17
19:11
Periodicals
Facebook seeks deals with publishers for video production, Recode says »

As part of a bid to push…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

HLX

Helix Energy

$7.09

-0.19 (-2.61%)

18:25
04/23/17
04/23
18:25
04/23/17
18:25
Earnings
Helix Energy reports Q1 EPS (11c), consensus (13c) »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 01

    May

CMCSA

Comcast

$38.16

0.16 (0.42%)

, CMCSK

Comcast

18:17
04/23/17
04/23
18:17
04/23/17
18:17
Hot Stocks
Box Office Battle: 'Fate Of The Furious' nears global $1B in second weekend »

Comcast's (CMCSA)…

CMCSA

Comcast

$38.16

0.16 (0.42%)

CMCSK

Comcast

FOX

21st Century Fox

$30.22

-0.33 (-1.08%)

FOXA

21st Century Fox

$30.70

-0.37 (-1.19%)

DIS

Disney

$114.44

-0.35 (-0.30%)

TWX

Time Warner

$99.84

-0.16 (-0.16%)

LGF.A

Lionsgate

$26.08

0.11 (0.42%)

LGF.B

Lionsgate

$23.90

0.01 (0.04%)

SNE

Sony

$33.68

0.85 (2.59%)

VIA

Viacom

$45.05

-1 (-2.17%)

VIAB

Viacom

$43.10

-1.23 (-2.77%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 03

    May

  • 04

    May

  • 10

    May

  • 24

    May

  • 25

    May

  • 15

    Jun

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

17:46
04/23/17
04/23
17:46
04/23/17
17:46
Earnings
C.R. Bard raises FY17 adjusted EPS to $11.65-$11.90 from $11.45-$11.75 »

EPS consensus $11.64.…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

17:43
04/23/17
04/23
17:43
04/23/17
17:43
Earnings
C.R. Bard sees Q2 adjusted EPS $2.75-$2.85, consensus $2.87 »

Sees Q2 revenue growth…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

, BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

17:41
04/23/17
04/23
17:41
04/23/17
17:41
Earnings
C.R. Bard reports Q1 adjusted EPS $2.87, consensus $2.65 »

Reports Q1 revenue…

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:38
04/23/17
04/23
17:38
04/23/17
17:38
Hot Stocks
Becton Dickinson names Polen as president, says will lead Bard segment »

BD (BDX) announced the…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

HCMLY

LafargeHolcim

$11.56

-0.1 (-0.86%)

17:32
04/23/17
04/23
17:32
04/23/17
17:32
Periodicals
LafargeHolcim CEO set to step down, FT reports »

LafargeHolcim CEO Eric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:30
04/23/17
04/23
17:30
04/23/17
17:30
Hot Stocks
Becton Dickinson outlines strategic highlights of C.R. Bard acquisition »

Expanding on the…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

KLRE

KLR Energy Acquisition

$10.40

-0.02 (-0.19%)

17:29
04/23/17
04/23
17:29
04/23/17
17:29
Conference/Events
KLR Energy Acquisition to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:23
04/23/17
04/23
17:23
04/23/17
17:23
Hot Stocks
BD sees forming third business segment, says Bard CEO to join board »

Commenting on its…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:20
04/23/17
04/23
17:20
04/23/17
17:20
Hot Stocks
BD sees high single-digit EPS accretion in FY19 »

"This financially…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:18
04/23/17
04/23
17:18
04/23/17
17:18
Hot Stocks
Becton Dickinson says expects to continue buyback suspension »

"BD expects to…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:16
04/23/17
04/23
17:16
04/23/17
17:16
Hot Stocks
Becton Dickinson to acquire C.R. Bard in $24B cash and stock deal »

BD (BDX) and C. R. Bard…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

, BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

17:10
04/23/17
04/23
17:10
04/23/17
17:10
Hot Stocks
Breaking Hot Stocks news story on Becton Dickinson, C.R. Bard »

Becton Dickinson to…

BDX

Becton Dickinson

$185.29

-0.76 (-0.41%)

BCR

C.R. Bard

$253.07

-1.7 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 03

    May

  • 04

    May

  • 06

    Jun

CS

Credit Suisse

$14.45

-0.09 (-0.62%)

17:07
04/23/17
04/23
17:07
04/23/17
17:07
Periodicals
Credit Suisse to determine capital raise plan after annual meeting, Reuters says »

Credit Suisse will make a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$142.27

-0.17 (-0.12%)

17:04
04/23/17
04/23
17:04
04/23/17
17:04
Periodicals
Uber CEO ordered iPhone tracking, was scolded by Tim Cook, NYT says »

Beginning in 2014, ride…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

AVID

Avid Technology

$5.11

0.19 (3.86%)

, MSFT

Microsoft

$66.40

0.9 (1.37%)

16:30
04/23/17
04/23
16:30
04/23/17
16:30
Hot Stocks
Avid announces strategic cloud alliance with Microsoft »

Avid (AVID) announced it…

AVID

Avid Technology

$5.11

0.19 (3.86%)

MSFT

Microsoft

$66.40

0.9 (1.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 02

    May

  • 09

    May

  • 09

    May

15:44
04/23/17
04/23
15:44
04/23/17
15:44
Conference/Events
Wolfe Research utilities analyst holds an analyst/industry conference call »

Utilities Analyst…

OA

Orbital ATK

$97.28

-0.65 (-0.66%)

15:32
04/23/17
04/23
15:32
04/23/17
15:32
Hot Stocks
Breaking Hot Stocks news story on Orbital ATK »

Orbital ATK says Cygnus…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTRV

ContraVir Pharmaceuticals

$1.41

-0.09 (-6.00%)

15:30
04/23/17
04/23
15:30
04/23/17
15:30
Hot Stocks
ContraVir presents data on hepatitis B candidates TXL, CRV431 »

ContraVir Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASPS

Altisource

$24.05

-1.39 (-5.46%)

, NRZ

New Residential

$16.34

-0.05 (-0.31%)

15:30
04/23/17
04/23
15:30
04/23/17
15:30
Conference/Events
Piper Jaffray specialty finance analyst holds analyst/industry conference call »

Regional Banks &…

ASPS

Altisource

$24.05

-1.39 (-5.46%)

NRZ

New Residential

$16.34

-0.05 (-0.31%)

OCN

Ocwen

$2.42

-0.07 (-2.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 03

    May

  • 24

    May

MRK

Merck

$61.89

-0.66 (-1.06%)

15:27
04/23/17
04/23
15:27
04/23/17
15:27
Hot Stocks
Merck reports new Phase 2 MK-3682B data »

Merck announced the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 03

    May

  • 07

    May

  • 10

    May

  • 27

    May

  • 09

    Jun

  • 14

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.